Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin

This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD) who are switched from a stable dose of recombinant human erythropoietin (rhEPO). The data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials.

Study Overview

• Status: Completed
• Conditions: Anaemia
• Intervention / Treatment: Drug: Placebo; Drug: GSK1278863; Drug: rhEPO

• Study Type: Interventional
• Enrollment (Actual): 216
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Liverpool, New South Wales, Australia, 2170
      • GSK Investigational Site
    • Westmead, New South Wales, Australia, 2145
      • GSK Investigational Site
  • Queensland
    • Woolloongabba, Queensland, Australia, 4102
      • GSK Investigational Site
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • GSK Investigational Site
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • GSK Investigational Site
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2R 0X7
      • GSK Investigational Site
    • Edmonton, Alberta, Canada, T6G 2B7
      • GSK Investigational Site
  • Ontario
    • Kitchener, Ontario, Canada, N2G 1G3
      • GSK Investigational Site
    • London, Ontario, Canada, N6A 5A5
      • GSK Investigational Site
    • Sudbury, Ontario, Canada, P3E 5J1
      • GSK Investigational Site
  • Quebec
    • Montreal, Quebec, Canada, H1T 2M4
      • GSK Investigational Site
• Czechia
  • Liberec, Czechia, 460 63
    • GSK Investigational Site
  • Louny, Czechia, 440 01
    • GSK Investigational Site
  • Most, Czechia, 434 64
    • GSK Investigational Site
  • Praha 10, Czechia, 100 34
    • GSK Investigational Site
  • Praha 2, Czechia, 128 08
    • GSK Investigational Site
  • Praha 4, Czechia, 142 00
    • GSK Investigational Site
  • Sokolov, Czechia, 356 01
    • GSK Investigational Site
• Denmark
  • Odense C, Denmark, 5000
    • GSK Investigational Site
  • Roskilde, Denmark, DK-4000
    • GSK Investigational Site
• France
  • Amiens cedex 1, France, 80054
    • GSK Investigational Site
  • Bordeaux, France, 33000
    • GSK Investigational Site
  • Caen Cedex 9, France, 14033
    • GSK Investigational Site
  • Paris Cedex 15, France, 75743
    • GSK Investigational Site
• Germany
  • Berlin, Germany, 12053
    • GSK Investigational Site
  • Hamburg, Germany, 22297
    • GSK Investigational Site
  • Baden-Wuerttemberg
    • Mannheim, Baden-Wuerttemberg, Germany, 68167
      • GSK Investigational Site
  • Bayern
    • Muenchen, Bayern, Germany, 81675
      • GSK Investigational Site
  • Mecklenburg-Vorpommern
    • Demmin, Mecklenburg-Vorpommern, Germany, 17109
      • GSK Investigational Site
  • Nordrhein-Westfalen
    • Duesseldorf, Nordrhein-Westfalen, Germany, 40210
      • GSK Investigational Site
  • Sachsen
    • Leipzig, Sachsen, Germany, 04129
      • GSK Investigational Site
• Hungary
  • Budapest, Hungary, 1115
    • GSK Investigational Site
  • Esztergom, Hungary, 2500
    • GSK Investigational Site
  • Pécs, Hungary, 7624
    • GSK Investigational Site
  • Pécs, Hungary, 7633
    • GSK Investigational Site
• Japan
  • Aichi, Japan, 441-8023
    • GSK Investigational Site
  • Ehime, Japan, 790-0952
    • GSK Investigational Site
  • Ehime, Japan, 790-0962
    • GSK Investigational Site
  • Fukuoka, Japan, 803-0844
    • GSK Investigational Site
  • Kyoto, Japan, 617-0813
    • GSK Investigational Site
  • Niigata, Japan, 940-0053
    • GSK Investigational Site
  • Wakayama, Japan, 640-8335
    • GSK Investigational Site
  • Yamagata, Japan, 990-0834
    • GSK Investigational Site
• Korea, Republic of
  • Anyang-Si Gyeonggi-do, Korea, Republic of, 431-070
    • GSK Investigational Site
  • Daegu, Korea, Republic of, 700-721
    • GSK Investigational Site
  • Daejeon, Korea, Republic of, 301-721
    • GSK Investigational Site
  • Gwangju, Korea, Republic of, 501-757
    • GSK Investigational Site
  • Incheon, Korea, Republic of, 405-760
    • GSK Investigational Site
  • Seoul, Korea, Republic of, 120-752
    • GSK Investigational Site
• Norway
  • Oslo, Norway, 0405
    • GSK Investigational Site
  • Oslo, Norway, 0027
    • GSK Investigational Site
  • Stavanger, Norway, 4011
    • GSK Investigational Site
  • Trondheim, Norway, 7006
    • GSK Investigational Site
  • Tønsberg, Norway, 3116
    • GSK Investigational Site
• Poland
  • Krakow, Poland, 31-501
    • GSK Investigational Site
  • Tarnow, Poland, 33-100
    • GSK Investigational Site
  • Warszawa, Poland, 02-507
    • GSK Investigational Site
  • Zabrze, Poland, 41-800
    • GSK Investigational Site
• Russian Federation
  • Kaluga, Russian Federation, 248007
    • GSK Investigational Site
  • Krasnodar, Russian Federation, 350029
    • GSK Investigational Site
  • Krasnogorsk, Russian Federation, 143400
    • GSK Investigational Site
  • Moscow, Russian Federation, 125101
    • GSK Investigational Site
  • Mytischi, Russian Federation, 141009
    • GSK Investigational Site
  • Novosibirsk, Russian Federation, 630087
    • GSK Investigational Site
  • St. Petersburg, Russian Federation, 191104
    • GSK Investigational Site
  • St. Petersburg, Russian Federation, 194354
    • GSK Investigational Site
  • Yaroslavl, Russian Federation, 150062
    • GSK Investigational Site
• Spain
  • Alcala de Henares, Spain, 28805
    • GSK Investigational Site
  • Alicante, Spain, 03010
    • GSK Investigational Site
  • Almería, Spain, 04009
    • GSK Investigational Site
  • Badalona, Spain, 08916
    • GSK Investigational Site
  • Barcelona, Spain, 08907
    • GSK Investigational Site
  • Córdoba, Spain, 14004
    • GSK Investigational Site
  • Granada, Spain, 18014
    • GSK Investigational Site
  • Madrid, Spain, 28007
    • GSK Investigational Site
  • Madrid, Spain, 28224
    • GSK Investigational Site
  • San Sebastian de los Reyes, Spain, 28702
    • GSK Investigational Site
  • Santander, Spain, 39008
    • GSK Investigational Site
  • Santiago de Compostela, Spain, 15706
    • GSK Investigational Site
• Sweden
  • Karlstad, Sweden, SE-651 85
    • GSK Investigational Site
  • Stockholm, Sweden, SE-141 86
    • GSK Investigational Site
  • Uppsala, Sweden, SE-751 85
    • GSK Investigational Site
  • Örebro, Sweden, SE-701 85
    • GSK Investigational Site
• United Kingdom
  • Chelmsford, United Kingdom, CM1 7ET
    • GSK Investigational Site
  • Dorchester, United Kingdom, DT1 2JY
    • GSK Investigational Site
  • Dundee, United Kingdom, DD1 9SY
    • GSK Investigational Site
  • Hull, United Kingdom, HU3 2JZ
    • GSK Investigational Site
  • London, United Kingdom, E1 1BB
    • GSK Investigational Site
  • Manchester, United Kingdom, M13 9WL
    • GSK Investigational Site
  • Oxford, United Kingdom, OX3 7LE
    • GSK Investigational Site
• United States
  • California
    • Azusa, California, United States, 91702
      • GSK Investigational Site
    • Los Angeles, California, United States, 90025
      • GSK Investigational Site
    • Los Angeles, California, United States, 90022
      • GSK Investigational Site
    • San Dimas, California, United States, 91773
      • GSK Investigational Site
    • West Hills, California, United States, 91307
      • GSK Investigational Site
  • Florida
    • Lauderdale Lakes, Florida, United States, 33313
      • GSK Investigational Site
    • Pembroke Pines, Florida, United States, 33028
      • GSK Investigational Site
  • Georgia
    • Macon, Georgia, United States, 31217
      • GSK Investigational Site
  • Illinois
    • Evergreen Park, Illinois, United States, 60805
      • GSK Investigational Site
  • Maryland
    • Bethesda, Maryland, United States, 20814
      • GSK Investigational Site
  • Missouri
    • Farmington, Missouri, United States, 63640
      • GSK Investigational Site
  • New York
    • Amherst, New York, United States, 14226
      • GSK Investigational Site
    • Bronx, New York, United States, 10461
      • GSK Investigational Site
  • North Carolina
    • Charlotte, North Carolina, United States
      • GSK Investigational Site
  • Tennessee
    • Knoxville, Tennessee, United States, 37923
      • GSK Investigational Site
  • Texas
    • San Antonio, Texas, United States, 78229
      • GSK Investigational Site
    • Temple, Texas, United States, 76502
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• - Subjects are eligible if they meet all of the inclusion criteria below:
• General criteria
• Age: >=18 years of age. (Week -4 verification only)
• Gender: Female and male subjects. (Week -4 verification only) Females: If of childbearing potential, must agree to use one of the approved contraception methods, from Screening until completion of the Follow-up Visit OR of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, or oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 International units per liter (IU/L) and estradiol <=10 picomole per liter (pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2 weeks must elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method;
• Q-T Interval Corrected for Heart Rate (QTc): Bazett's Correction of QT Interval (QTcB) <470 millisecond (msec) or QTcB <480 msec in subjects with bundle branch block. There is no QTc inclusion criterion for a subject with a predominantly paced rhythm.
• CKD-related criteria
• Dialysis frequency: On hemodialysis (HD) three to five times weekly for at least 4 weeks prior to Week -4 Screening through Week 4. NOTE: Combination methods including hemofiltration (HF) or ultrafiltration (UF) with HD are allowed. However, the type of dialysis (HD, hemodiafiltration (HDF) or UF) should not change during the study.
• Dialysis adequacy: A single-pool dialyzer clearance multiplied by dialyzer time divided by volume of distribution of urea (Kt/Vurea) of >=1.2 based on a historical value obtained within the prior month in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio (URR) of at least 65%. NOTE: Only needs confirming at Week -4.
• Hemoglobin: Baseline Hgb of 9.0-11.5 g/dL (may rescreen in a minimum of 2 weeks).
• Stable rhEPO dose: Using the same rhEPO (epoetins or their biosimilars, or darbepoetin) with total weekly doses varying by no more than 50% during the 4 weeks prior to Week -4. At Day 1 (randomization), confirm that total weekly doses varied by no more than 50% during the screening period.
• Iron replacement therapy: Subjects may be on stable maintenance oral or IV (<=100 mg/week) iron supplementation. If subjects are on oral or IV iron, then doses must be stable for the 4 weeks prior to Week -4, during the screening phase, and through the first 4 weeks after Randomization.

Exclusion Criteria:

• Subjects are not eligible if they meet any of the exclusion criteria below:
• CKD-related criteria
• Dialysis modality: Planned change from HD to peritoneal dialysis within the study time period.
• Renal transplant: Pre-emptive or scheduled renal transplant.
• High rhEPO dose: An epoetin dose of >=360 IU/Kg/Week IV or >=250 IU/kg/week subcutaneous (SC) or darbepoetin dose of >=1.8 microgram (µg)/Kg/Week IV or SC within the prior 8 weeks through Day 1 (randomization).
• Use of methoxy polyethylene glycol epoetin beta within the prior 8 weeks through Day 1 (randomization).
• Laboratory test-based criteria (Week -4 verification only)
• Vitamin B12: At or below the lower limit of the reference range (may rescreen in a minimum of 8 weeks).
• Folate: <2.0 nanogram (ng)/mL (<4.5 nanomole (nmol)/L) (may rescreen in a minimum of 4 weeks).
• Ferritin: <100 ng/mL (<100 Micrograms per liter).
• Transferrin saturation (TSAT): Outside of the reference range.
• Cardiovascular disease-related criteria
• Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Screening through Day 1 (randomization).
• Stroke or transient ischemic attack: Within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
• Heart failure: Class III/IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system diagnosed prior to Week -4 Screening through Day 1 (randomization); Symptomatic right heart failure diagnosed prior to Week -4 Screening through Day 1 (randomization).
• Hypertension: Defined using pre-dialysis vitals (Week -4, Day 1) of diastolic blood pressure (DBP) >100 millimeters of mercury (mmHg) or systolic blood pressure (SBP) >170 mmHg.
• Thrombotic disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention), except vascular access thrombosis, within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
• Other disease-related criteria
• Ophthalmology disease: Meeting any ophthalmologic-related exclusion criteria determined at the Screening ophthalmology exam.
• Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Week -4 Screening through Day 1 (randomization).
• Hematological disease: Any hematological disease including those affecting platelets, white or red blood cells (e.g. sickle cell anemia, myelodysplastic syndromes, hematological malignancy, myeloma, hemolytic anemia and thalassemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia other than renal disease diagnosed prior to Week -4 Screening through Day 1 (randomization).
• Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [alanine transaminase (ALT) or aspartate transaminase (AST) > 2.0 x upper limit of normal (ULN) or total bilirubin > 1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study. NOTE: Those with Hepatitis B or Hepatitis C are eligible provided these exclusions are not met.
• Major surgery: Major surgery (excluding vascular access surgery) within the prior 8 weeks, during the Week -4 Screening phase or planned during the study.
• Transfusion: Blood transfusion within the prior 8 weeks, during the Week -4 Screening phase or an anticipated need for blood transfusion during the study.
• GI Bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease OR clinically significant GI bleeding within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
• Acute infection: Clinical evidence of acute infection or history of infection requiring intravenous (IV) antibiotic therapy within the 8 weeks prior to Week -4 Screening through Day 1 (randomization). NOTE: IV antibiotics as prophylaxis are allowed.
• Malignancy: Subjects with a history of malignancy within the prior 5 years, who receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders); with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to Week -4 Screening through Day 1 (randomization).
• Concomitant medication and other Investigational Product-related criteria
• Severe allergic reactions: History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product.
• Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Week -4 Screening until the Follow-up Visit.
• Prior investigational product exposure: The Subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days from Week -4 Screening through Day 1 (randomization).
• General health-related criteria
• Other Conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the Investigator considers would put the subject at unacceptable risk.
• Pregnancy or Lactation: Pregnant females as determined by positive serum human chorionic gonadotropin (hCG) test OR women who are lactating at Week -4 Screening or during the trial.
• Other Eligibility Criteria Considerations
• Laboratory eligibility criteria will be assessed according to the central laboratory results for the screening samples.
• Subjects who fail screening may be rescreened as soon as the investigator feels they may have become eligible. However, an individual subject may not rescreen more than twice. There is no predetermined amount of time that the investigator needs to wait to rescreen a previously ineligible subject, except those excluded for Hgb or folate who may only rescreen in 2 and 4 weeks, respectively, and those excluded for Vitamin B12 who may rescreen in 8 weeks

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GSK1278863 4 mg; Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.	Drug: GSK1278863; Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
Experimental: GSK1278863 6 mg; Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.	Drug: GSK1278863; Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
Experimental: GSK1278863 8 mg; Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.	Drug: GSK1278863; Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
Experimental: GSK1278863 10 mg; Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.	Drug: GSK1278863; Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
Experimental: GSK1278863 12 mg; Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.	Drug: GSK1278863; Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
Active Comparator: Control; Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.	Drug: Placebo; Matching placebo tablet for GSK1278863; Drug: rhEPO; rhEPO will be procured from local market

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Hemoglobin (Hgb) at Week 4	Baseline Hgb value was the average of three Hgb values taken during screening period at Week (W) -4, W-2 and Day 1. Change from Baseline in Hgb was calculated as W4 value minus the Baseline value. To model the dose-response relationship a four-parameter Emax model was used. The dose response dataset was based on all non-missing data collected up to W4. Participants (par.) who had a Week 2 Hgb measurement, but a missing Week 4 Hgb measurement were included with a change from Baseline at Week 4 value imputed as twice the change from Baseline at Week 2. E0 is the expected Hgb change from Baseline for a par. receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a par. receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Alpha is the coefficient of the model covariate for centred Baseline.	Baseline (Week -4, Week-2 and Day 1) and Week 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hgb Concentration at Week 24	Hgb values measured at Week 24 are presented.	Week 24
Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	The percentage of time in Hgb target range between Weeks 20 and 24 for a participant was calculated by dividing the total number of days that Hgb was within the target range (10.0 to 11.5 g/dL) while on treatment during Weeks 20 to 24 (using linear interpolation) by the total number of days the participant remained on treatment during the defined period. Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated.	Week 20 to Week 24
Number of Participants With Hgb in the Target Range at Week 24	The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 24 was recorded for each arm.	Week 24
Number of Participants Reaching Pre-defined Hgb Stopping Criteria	The number of participants who reached the Hgb stopping criteria of Hgb concentration <7.5 g/dL were presented.	Up to 24 weeks
Maximum Observed Change From Baseline in Erythropoietin (EPO)	Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-dose values minus the Baseline value.	Baseline (Day 1) to Week 28
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)	Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF was recorded for each arm. Baseline value for VEGF is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.	Baseline (Day 1) to Week 28
Population Plasma PK Parameters of GSK1278863 and Metabolites	Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose [PrD), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour [hr] post-dose [PoD), and at W20 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.	Day 1, Week 4, and Week 20
Percent Change From Baseline in Hepcidin at Week 24	Hepcidin is a regulator of iron metabolism. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.	Baseline (Day 1) and Week 24
Change From Baseline in Ferritin at Week 24	Baseline value for ferritin is the pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 24 value minus the Baseline value.	Baseline (Day 1) and Week 24
Change From Baseline in Transferrin at Week 24	Baseline value for transferrin is the pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 24 value minus the Baseline value.	Baseline (Day 1) and Week 24
Percent Change From Baseline in Transferrin Saturation at Week 24	Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline =: 100*(exp(Mean change log scale)-1).	Baseline (Day 1) and Week 24
Change From Baseline in Total Iron at Week 24	Baseline value for total iron is the pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 24 value minus the Baseline value.	Baseline (Day 1) and Week 24
Change From Baseline in Total Iron Binding Capacity at Week 24	Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 24 value minus the Baseline value.	Baseline (Day 1) and Week 24
Change From Baseline in Reticulocyte Hemoglobin at Week 24	Baseline value for reticulocyte hemoglobin is the pre-dose value on Day 1. Change from Baseline in reticulocyte hemoglobin was calculated as the Week 24 value minus the Baseline value.	Baseline (Day 1) and Week 24
Change From Baseline in Hematocrit at Week 24	Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 24 value minus the Baseline value.	Baseline (Day 1) and Week 24
Change From Baseline in Red Blood Cells at Week 24	Baseline value for red blood cells is the pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 24 value minus the Baseline value.	Baseline (Day 1) and Week 24
Change From Baseline in Reticulocyte Count at Week 24	A reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline value for reticulocyte count is the pre-dose value on Day 1. Change from Baseline in reticulocyte count was calculated as the Week 24 value minus the Baseline value.	Baseline (Day 1) and Week 24

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.

Study record dates

Study Major Dates

• Study Start: November 1, 2013
• Primary Completion (Actual): February 1, 2015
• Study Completion (Actual): February 6, 2015

Study Registration Dates

• First Submitted: October 24, 2013
• First Submitted That Met QC Criteria: October 31, 2013
• First Posted (Estimate): November 6, 2013

Study Record Updates

• Last Update Posted (Actual): June 8, 2018
• Last Update Submitted That Met QC Criteria: May 10, 2018
• Last Verified: May 1, 2018

More Information

Terms related to this study

• Keywords: hemoglobin; Anemia; pharmacokinetics; Chronic kidney disease; hemodialysis; GSK1278863; erythropoiesis stimulating agents; recombinant human erythropoietin
• Additional Relevant MeSH Terms: Urologic Diseases; Hematologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic; Anemia
• Other Study ID Numbers: 113633